KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2024 - 2025)

Historic Deferred Taxes for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Q4 2025 value amounting to -$27.2 million.

  • Alnylam Pharmaceuticals' Deferred Taxes rose 7470.04% to -$27.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.2 million, marking a year-over-year increase of 9794.12%. This contributed to the annual value of -$2.2 million for FY2025, which is 9794.12% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Deferred Taxes is -$27.2 million, which was up 7470.04% from $5.6 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Deferred Taxes peaked at $9.7 million during Q2 2025, and registered a low of -$107.4 million during Q4 2024.